These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
480 related articles for article (PubMed ID: 32297449)
1. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial. Wachter R; Shah SJ; Cowie MR; Szecsödy P; Shi V; Ibram G; Zhao Z; Gong J; Klebs S; Pieske B ESC Heart Fail; 2020 Jun; 7(3):856-864. PubMed ID: 32297449 [TBL] [Abstract][Full Text] [Related]
2. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial. Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR; JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839 [TBL] [Abstract][Full Text] [Related]
3. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Solomon SD; Braunwald E; J Am Coll Cardiol; 2023 Jul; 82(1):1-12. PubMed ID: 37212758 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ; J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP; N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794 [TBL] [Abstract][Full Text] [Related]
8. Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction. Shah SJ; Cowie MR; Wachter R; Szecsödy P; Shi V; Ibram G; Hu M; Zhao Z; Gong J; Pieske B Eur J Heart Fail; 2021 Sep; 23(9):1541-1551. PubMed ID: 34170062 [TBL] [Abstract][Full Text] [Related]
9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374 [TBL] [Abstract][Full Text] [Related]
10. Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions. Bozkurt B; Nair AP; Misra A; Scott CZ; Mahar JH; Fedson S JACC Basic Transl Sci; 2023 Jan; 8(1):88-105. PubMed ID: 36777165 [TBL] [Abstract][Full Text] [Related]
11. Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial. Shaddy R; Burch M; Kantor PF; Solar-Yohay S; Garito T; Zhang S; Kocun M; Mao C; Cilliers A; Wang X; Canter C; Rossano J; Wallis G; Menteer J; Daou L; Kusa J; Tokel K; Dilber D; Xu Z; Xiao T; Halnon N; Daly KP; Bock MJ; Zuckerman W; Singh TP; Chakrabarti M; Levitas A; Senni M; Grutter G; Kim GB; Song J; Lee HD; Chen CK; Sanchez-de-Toledo J; Law Y; Wanitkun S; Cui Y; Anjos R; Mese T; Bonnet D; Circulation; 2024 Nov; 150(22):1756-1766. PubMed ID: 39319469 [TBL] [Abstract][Full Text] [Related]
12. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ; JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471 [TBL] [Abstract][Full Text] [Related]
14. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
15. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284 [TBL] [Abstract][Full Text] [Related]
17. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. Marques da Silva P; Aguiar C Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335 [TBL] [Abstract][Full Text] [Related]
18. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. Myhre PL; Vaduganathan M; Claggett B; Packer M; Desai AS; Rouleau JL; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD J Am Coll Cardiol; 2019 Mar; 73(11):1264-1272. PubMed ID: 30846338 [TBL] [Abstract][Full Text] [Related]
19. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Selvaraj S; Claggett BL; Pfeffer MA; Desai AS; Mc Causland FR; McGrath MM; Anand IS; van Veldhuisen DJ; Kober L; Janssens S; Cleland JGF; Pieske B; Rouleau JL; Zile MR; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD Eur J Heart Fail; 2020 Nov; 22(11):2093-2101. PubMed ID: 32840930 [TBL] [Abstract][Full Text] [Related]